Publication details

Macugen v léčbě vlhké formy VPMD, první zkušenosti

Title in English Macugen in treatment of wet form of AMD, first experience
Authors

KOLÁŘ Petr VIŽĎOVÁ Drahomíra

Year of publication 2007
Type Conference abstract
MU Faculty or unit

Faculty of Medicine

Citation
Description This work assesses the results of applying the first selective antagonist of VEGF Macugen (pegaptanib) for subfoveal choroidal neovascular membrane (CNV) in age-related macular degeneration (ARMD). Macugen is a modified oligonucleotide that binds specifically to the extracellular VEGF165. Study included patients treated at our institution with Macugen for wet AMD in 2007.

You are running an old browser version. We recommend updating your browser to its latest version.

More info